@article {10.3844/ajidsp.2008.237.243,
article_type = {journal},
title = {Cefepime Monotherapy is as Effective as Ceftriaxone Plus Amikacin in Pediatric Patients with Cancer and High-Risk Febrile Neutropenia: A Randomized Comparison},
author = {Pereira, Carlos Alberto Pires and Petrilli, Antonio Sérgio and Carlesse, Fabianne Altruda and Luisi, Flávio Augusto Vercillo and Barros da Silva, Kátia Verônica Torres and De Martino Lee, Maria Lúcia},
volume = {4},
number = {4},
year = {2008},
month = {Dec},
pages = {237-243},
doi = {10.3844/ajidsp.2008.237.243},
url = {https://thescipub.com/abstract/ajidsp.2008.237.243},
abstract = {The empirical use of antibiotic therapies is widely accepted in patients with fever and neutropenia during cancer chemotherapy. The use of intravenous monotherapy with broad-spectrum antibiotics in patients with high-risk of complications is an appropriate alternative. However, few data are available in pediatric patients. We conducted a prospective, randomized, open study in patients with lymphoma or leukemia who had fever and neutropenia during chemotherapy. Patients were randomized to receive cefepime (CFP) or ceftriaxone plus amikacin (CFT+AK). A total of 57 patients with 125 episodes of fever and neutropenia were evaluated (CFP, 62 and CFT + AK, 63 episodes). The mean neutrophil count at admission was 118.6 cells mm-3 (CFP) and 107 cells mm-3 (CFT+AK). The mean duration of neutropenia was 9.0 days (CFP) and 8.0 days (CFT+AK). Analyzing only the first episodes of each patient, CFP treatment was successful in 65.5% of the episodes and CFT+AK were successful in 64.3%. Overall rates of success with modification were 90% (CFP) and 89% (CFT+AK). No major treatment-emergent toxicity was reported. Monotherapy with CFP seems to be as effective and safe as the combination of CFT+AK for initial empirical therapy in children and adolescents with NF.},
journal = {American Journal of Infectious Diseases},
publisher = {Science Publications}
}